ES2051696T3 - Un procedimiento para la preparacion de compuestos farmacologicos. - Google Patents
Un procedimiento para la preparacion de compuestos farmacologicos.Info
- Publication number
- ES2051696T3 ES2051696T3 ES86906498T ES86906498T ES2051696T3 ES 2051696 T3 ES2051696 T3 ES 2051696T3 ES 86906498 T ES86906498 T ES 86906498T ES 86906498 T ES86906498 T ES 86906498T ES 2051696 T3 ES2051696 T3 ES 2051696T3
- Authority
- ES
- Spain
- Prior art keywords
- carbon atoms
- formula
- alkyl
- compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 16
- 238000000034 method Methods 0.000 title abstract 2
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 34
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 150000003839 salts Chemical class 0.000 abstract 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 238000006243 chemical reaction Methods 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 239000011734 sodium Substances 0.000 abstract 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 3
- 229910052708 sodium Inorganic materials 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- -1 alkoxy atoms amino- Chemical class 0.000 abstract 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 125000002071 phenylalkoxy group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical class [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
Procedimiento para la preparación de un compuesto de fórmula I, **fórmula** y sus sales fisiológicamente aceptables, en donde X es -S- o -SO-; R1, R2, R3 y R4 , que pueden ser iguales o diferentes, son: (a) H (b) alquilo que contiene 1-6 átomos de carbono (c) cicloalquilo que contiene 3-7 átomos de carbono (d) alcoxi que contiene 1-6 átomos de carbono (e) alcoxialquilo que contiene 1-3 átomos de carbono en cada parte alquílica (f) alcoxialcoxi que contiene 1-3 átomos de carbono en cada parte alquílica (g) halógeno R5 es: (a) alquilo que contiene 1-6 átomos de carbono (b) alquilo mono- o dihidroxi-sustituido que contiene 1-6 átomos de carbono (c) alquilo amino-, monoalquil (1-3 átomos de carbono)-amino- y dialquil (1-3 átomos de carbono en cada parte alquílica)-amino-sustituido que contiene 1-6 átomos de carbono, opcionalmente en forma de una sal, v.g. hidrocloruro (d) alquilo carboxi-sustituido que contiene 1-7 átomos de carbono, opcionalmente en forma de una sal, v.g. sal sódica o potásica (e) cicloalquilo que contiene 3-7 átomos de carbono (f) alcoxi que contiene 1-6 átomos de carbono (g) alcoxi mono- o dihidroxi-sustituido que contiene 1-6 átomos de carbono (h) alcoxi amino-, monoalquil (1-3 átomos de carbono)-amino- y dialquil (1-3 átomos de carbono en cada parte alquílica)-amino-sustituido que contiene 1-6 átomos de carbono, opcionalmente en forma de una sal, v.g. hidrocloruro (i) alcoxi carboxi-sustituido que contiene 1-7 átomos de carbono, opcionalmente en forma de una sal, v.g. sal sódica o potásica (j) alcoxialcoxi que contiene 1-3 átomos de carbono en cada parte alquílica (k) alquilamino que contiene 1-6 átomos de carbono (l) dialquilamino que contiene 1-4 átomos de carbono en cada parte alquílica (m) fenilo, opcionalmente sustituido con uno o dos sustituyentes, que pueden ser iguales o diferentes, seleccionados entre alquilo que contiene 1-4 átomos de carbono, alcoxi que contiene 1-4 átomos de carbono, halógeno, CF3, alcanoíloque contiene 2-5 átomos de carbono, alcoxicarbonilo que contiene 2-5 átomos de carbono y carboxi, en donde opcionalmente cualquier grupo carboxi puede estar en forma de una sal, v.g. sal sódica (n) fenoxi, opcionalmente sustituido con uno o dos sustituyentes, que pueden ser iguales o diferentes, seleccionados entre alquilo que contiene 1-4 átomos de carbono, alcoxi que contiene 1-4 átomos de carbono, alcoxicarbonilo que contiene 2-5 átomos de carbono y carboxi, en donde opcionalmente cualquiergrupo carboxi puede estar en forma de una sal, v.g. sal sódica (o) fenilalcoxi que contiene 1-6 átomos de carbono en la parte alcoxica, en donde opcionalmente la parte arílica está sustituida con uno o dos sustituyentes, que pueden seriguales o diferentes, seleccionados entre alquilo que contiene 1-6 átomos de carbono, alcoxi que contiene 1-6 átomos de carbono y carboxi, en donde opcionalmente cualquiergrupo carboxi puede estaren forma de una sal, v.g. sal sódica. R6 y R8 son iguales o diferentes y se seleccionan entre: (a) H (b) alquilo que contiene 1-6 átomos de carbono R7 es: (a) H (b) alquilo que contiene 1-7 átomos de carbono (c) alcoxi que contiene 1-7 átomos de carbono (d) fenilo R9 es: (a) H (b) alquilo que contiene 1-4 átomos de carbono; con las salvedades de que: (a) R7 es hidRógeno, alquilo o fenilo cuando las condiciones siguientes (a1)-(a3) se satisfacen simultáneamente: (a1) R1 y R4 son ambos hidRógeno (a2) R2 y R3 se seleccionan entre los grupos hidRógeno, alquilo o alcoxi (a3) R5 es alquilo, alquilo carboxi-sustituido en su forma ácida, alquilo amino-sustituido, o R5 es fenilo, opcionalmente sustituido poRalquilo, alcoxi, halógeno o CF3 (b) R5 no es 2-metilpRopoxi cuando R1 , R2 , R3 , R4 , R6 , R7 , R8 y R9 son hidRógeno y X es S (c) y excluyendo los compuestos de fórmula I en los que: (c1) R1 , R2 , R3 , R4 , R6 , R7 , R8 y R9 son H,XesS y R5 es CH 3 (c2) R1 , R2 , R3 , R4 , R6 , R7 , R8 y R9 son H,XesS y R5 es (CH3)2CHCH2O- (c3) R1 , R2 , R3 , R4 , R6 , R7 , R8 y R9 son H,XesS y R5 es (CH3)2CH- por: A. Reacción de un compuesto de fórmula II, **fórmula** en donde R1 , R2 , R3 , R4 , R6 , R7 , R8 y X son como los definidos bajo la fórmula y M es un catión metálico, v.g. Na + , K + y Li + , o un ion de amonio cuaternario, v.g. tetRabutilamonio, con un compuesto de fórmula III, O = R5 -C-O-CHR9 -Y, en donde R5 y R9 son como los definidos bajo la fórmula I e Y es un halógeno, v.g. Cl, BRo I, o un grupo funcionalmente equivalente; B. Oxidación de un compuesto de fórmula I, **fórmula** en donde X es S y R1 , R2 , R3 , R4 , R5 , R6 , R7 , R8 y R9 tienen los significados ya indicados, paRa daRun compuesto de la misma fórmula I en el que X es SO; C. Para la preparación de compuestos de fórmula I en los que R9 es H, Reacción de un compuesto de fórmula IV, **fórmula** en donde R1 , R2 , R3 , R4 , R6 , R7 , R8 y X son como los definidos bajo la fórmula I, con un compuesto de fórmula V, R 5 COOH, o un derivado activado de éste, en donde R5 es como el antes definido bajo la fórmula I; D. Para la preparaciónde compuestos de fórmula I en los que R9 es H y que contienen un sustituyente amino, monoalquilamino o dialquilamino en el radical R5 , reacción de un compuesto de formula VI, **fórmula** en donde R1 , R2 , R3 , R4 , R6 , R7 , R8 y X son los definidos bajo la fórmula I y Z es halógeno, v.g. Cl, o un grupo funcionalmente equivalente, con un compuesto de fórmula VII, R11 / HN / R12 en donde R11 y R12 , que pueden ser iguales o diferentes, son H o alquilo que contiene 1-6 átomos de carbono; E. Para la preparación de compuestos de fórmula I en los que R9 es H y R5 es monoalquilamino que contiene 1-6 átomos de carbono, reacción de un compuesto de fórmula IV, **fórmula** en donde R1 , R2 , R3 , R4 , R6 , R7 , R8 y X son los definidos bajo la fórmulaI,con un compuesto de fórmula O=C=N-R 13 en donde R13 es alquilo que contiene 1-6 átomos de carbono, y después, en caso necesario, se eliminan los grupos protectores, y el compuesto de fórmula I así obtenido se convierte, si se desea, en una sal fisiológicamente aceptable o en un isómero óptico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8505112A SE8505112D0 (sv) | 1985-10-29 | 1985-10-29 | Novel pharmacological compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2051696T3 true ES2051696T3 (es) | 1994-07-01 |
Family
ID=20361960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES86906498T Expired - Lifetime ES2051696T3 (es) | 1985-10-29 | 1986-10-28 | Un procedimiento para la preparacion de compuestos farmacologicos. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5021433A (es) |
| EP (2) | EP0233284B1 (es) |
| JP (2) | JPH0780874B2 (es) |
| KR (1) | KR950009858B1 (es) |
| CN (1) | CN1022487C (es) |
| AT (1) | ATE79619T1 (es) |
| AU (1) | AU598491B2 (es) |
| CS (1) | CS272767B2 (es) |
| DD (1) | DD252375A5 (es) |
| DE (1) | DE3686483T2 (es) |
| DK (1) | DK320587D0 (es) |
| EG (1) | EG17753A (es) |
| ES (1) | ES2051696T3 (es) |
| FI (1) | FI91151C (es) |
| GR (1) | GR3006177T3 (es) |
| HU (1) | HU198474B (es) |
| IE (1) | IE59167B1 (es) |
| IL (1) | IL80437A0 (es) |
| IS (1) | IS1564B (es) |
| JO (1) | JO1502B1 (es) |
| LT (1) | LTIP1681A (es) |
| LV (1) | LV10270B (es) |
| MY (1) | MY101791A (es) |
| NO (1) | NO171365C (es) |
| NZ (1) | NZ218028A (es) |
| PH (1) | PH25319A (es) |
| PL (1) | PL150240B1 (es) |
| PT (1) | PT83647B (es) |
| SE (1) | SE8505112D0 (es) |
| WO (1) | WO1987002668A1 (es) |
| ZA (1) | ZA867716B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ222495A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | Benzimidazole derivatives and pharmaceutical compositions |
| AU617217B2 (en) * | 1988-09-20 | 1991-11-21 | Hisamitsu Pharmaceutical Co., Inc. | Novel dibenz(b,e)oxepin derivatives |
| IE64199B1 (en) * | 1988-12-22 | 1995-07-12 | Haessle Ab | Compound with gastric acid inhibitory effect and process for its preparation |
| SE8804629D0 (sv) * | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| US5274099A (en) * | 1989-12-20 | 1993-12-28 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
| US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| US5049674A (en) * | 1989-12-20 | 1991-09-17 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
| SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
| CA2083606C (en) * | 1990-06-20 | 2001-08-21 | Arne Elof Brandstrom | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
| ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| WO1995032957A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles |
| US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
| HUP0103464A3 (en) * | 1998-08-10 | 2002-11-28 | U S Government Represented By | Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them |
| US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US20040039027A1 (en) * | 2000-10-12 | 2004-02-26 | Keiji Kamiyama | Benzimidazole compounds, process for producing the same and use thereof |
| EP1437352A4 (en) * | 2001-09-25 | 2004-12-08 | Takeda Chemical Industries Ltd | BENZYMIDAZOLE COMPOUND, PROCESS FOR PRODUCING AND USING THE SAME |
| PE20040563A1 (es) * | 2002-06-14 | 2004-10-21 | Takeda Pharmaceutical | Compuesto de imidazol y metodo para su produccion |
| BR0312802A (pt) * | 2002-07-19 | 2005-04-19 | Michael E Garst | Pró-drogas de inibidores de bombas de próton |
| WO2004012659A2 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| EP2112920B1 (en) * | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| WO2005039640A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan Inc. | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs |
| US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| AU2005216863A1 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors |
| JP2007523163A (ja) * | 2004-02-18 | 2007-08-16 | アラーガン、インコーポレイテッド | プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物 |
| CA2561700A1 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| DK1740571T3 (da) | 2004-04-28 | 2009-11-02 | Hetero Drugs Ltd | Fremgangsmåde til fremstilling af pyridinylmethyl-1H-benzimidazolforbindelser i enantiomerisk beriget form eller som enkelte enantiomerer |
| ATE456566T1 (de) | 2004-05-28 | 2010-02-15 | Hetero Drugs Ltd | Neue stereoselektive synthese von benzimidazolsulfoxiden |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| CA2648280C (en) * | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2008036201A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
| EP2086543A2 (en) | 2006-10-27 | 2009-08-12 | The Curators of the University of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
| JP2011512416A (ja) | 2008-02-20 | 2011-04-21 | ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ | オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法 |
| AU2010339691B2 (en) * | 2010-01-07 | 2015-04-02 | Alkermes Pharma Ireland Limited | Prodrugs of heteraromatic compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR320097A (fr) * | 1902-04-01 | 1902-12-01 | Betts | Perfectionnements dans et relatifs au raffinage électrolytique du plomb et des alliages de plomb |
| FR1474663A (fr) * | 1966-04-06 | 1967-03-24 | Electrolyt Zinc Australasia | Procédé d'extraction de métaux |
| US4026776A (en) * | 1970-12-02 | 1977-05-31 | Mitsui Mining & Smelting Co., Ltd. | Method for producing high purity lead |
| US4045564A (en) * | 1974-02-18 | 1977-08-30 | Ab Hassle | Benzimidazole derivatives useful as gastric acid secretion inhibitors |
| SE418966B (sv) * | 1974-02-18 | 1981-07-06 | Haessle Ab | Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan |
| US3960681A (en) * | 1974-02-21 | 1976-06-01 | Mitsui Mining & Smelting Co., Ltd. | Method for producing electrolytic high purity lead using large-sized electrodes |
| SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| NZ181123A (en) * | 1975-06-30 | 1979-12-11 | Univ Melbourne | Treatment of mineralcontaining materials with an acid in the presence of fluoride ion |
| US3972790A (en) * | 1975-09-26 | 1976-08-03 | Uop Inc. | Production of metallic lead |
| IN148930B (es) * | 1977-09-19 | 1981-07-25 | Hoffmann La Roche | |
| US4189461A (en) * | 1977-11-30 | 1980-02-19 | Kennecott Copper Corporation | Metal leaching from concentrates using nitrogen dioxide in acids |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| FR2446863A1 (fr) * | 1979-01-22 | 1980-08-14 | Uop Inc | Procede perfectionne de recuperation de plomb |
| FR2453906A1 (fr) * | 1979-04-12 | 1980-11-07 | Uop Inc | Procede de preparation hydrometallurgique de plomb a l'aide d'une extraction par voie electrochimique |
| US4229271A (en) * | 1979-05-24 | 1980-10-21 | Rsr Corporation | Method of recovering lead values from battery sludge |
| US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
| CH644116A5 (de) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | Imidazolderivate. |
| FR2505876A1 (en) * | 1981-05-12 | 1982-11-19 | Noual Patrick | Selective winning of lead from sulphide ores - by leaching with hot aq. hydro:fluorosilicic acid soln. contg. hydrogen peroxide and air so only lead is dissolved |
| SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| US4500398A (en) * | 1984-06-20 | 1985-02-19 | The United States Of America As Represented By The Secretary Of The Interior | Production of lead from sulfides |
| AU568441B2 (en) * | 1984-09-24 | 1987-12-24 | Upjohn Company, The | 2-(pyridylalkenesulfinyl) benzimidazole derivatives |
| ZA856671B (en) * | 1984-09-24 | 1986-04-30 | Upjohn Co | N-substituted derivatives of 2-(pyridylaklenesulfinyl)benzimidazoles as gastric antisecretory agents |
-
1985
- 1985-10-29 SE SE8505112A patent/SE8505112D0/xx unknown
-
1986
- 1986-10-09 ZA ZA867716A patent/ZA867716B/xx unknown
- 1986-10-22 NZ NZ218028A patent/NZ218028A/xx unknown
- 1986-10-22 EG EG661/86A patent/EG17753A/xx active
- 1986-10-23 IE IE280586A patent/IE59167B1/en not_active IP Right Cessation
- 1986-10-24 PH PH34408A patent/PH25319A/en unknown
- 1986-10-27 JO JO19861502A patent/JO1502B1/en active
- 1986-10-27 DD DD86295633A patent/DD252375A5/de not_active IP Right Cessation
- 1986-10-27 MY MYPI86000038A patent/MY101791A/en unknown
- 1986-10-28 EP EP86906498A patent/EP0233284B1/en not_active Expired - Lifetime
- 1986-10-28 IS IS3156A patent/IS1564B/is unknown
- 1986-10-28 HU HU865443A patent/HU198474B/hu not_active IP Right Cessation
- 1986-10-28 EP EP86850378A patent/EP0221041A3/en active Pending
- 1986-10-28 DE DE8686906498T patent/DE3686483T2/de not_active Expired - Fee Related
- 1986-10-28 IL IL80437A patent/IL80437A0/xx not_active IP Right Cessation
- 1986-10-28 AU AU65429/86A patent/AU598491B2/en not_active Ceased
- 1986-10-28 JP JP61505700A patent/JPH0780874B2/ja not_active Expired - Lifetime
- 1986-10-28 KR KR1019870700555A patent/KR950009858B1/ko active IP Right Grant
- 1986-10-28 AT AT86906498T patent/ATE79619T1/de not_active IP Right Cessation
- 1986-10-28 WO PCT/SE1986/000493 patent/WO1987002668A1/en active IP Right Grant
- 1986-10-28 ES ES86906498T patent/ES2051696T3/es not_active Expired - Lifetime
- 1986-10-29 PT PT83647A patent/PT83647B/pt not_active IP Right Cessation
- 1986-10-29 CN CN86107595A patent/CN1022487C/zh not_active Expired - Lifetime
- 1986-10-29 PL PL1986262105A patent/PL150240B1/pl unknown
- 1986-10-29 CS CS782686A patent/CS272767B2/cs unknown
-
1987
- 1987-06-24 DK DK320587A patent/DK320587D0/da not_active Application Discontinuation
- 1987-06-26 NO NO872686A patent/NO171365C/no unknown
- 1987-06-29 FI FI872864A patent/FI91151C/sv not_active IP Right Cessation
-
1988
- 1988-05-12 US US07/195,343 patent/US5021433A/en not_active Expired - Fee Related
-
1992
- 1992-11-05 GR GR920402498T patent/GR3006177T3/el unknown
-
1993
- 1993-06-30 LV LVP-93-856A patent/LV10270B/xx unknown
- 1993-12-28 LT LTIP1681A patent/LTIP1681A/xx not_active Application Discontinuation
-
1994
- 1994-12-21 JP JP6318132A patent/JPH0826014B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2051696T3 (es) | Un procedimiento para la preparacion de compuestos farmacologicos. | |
| DK0447285T3 (da) | Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem | |
| DK135991D0 (da) | 1h-imidazooe4,5-caaquinolin-5-oxyforbindelse | |
| SE8404712L (sv) | Azolderivat, forfarande for deras framstellning, kompositioner innehallande dem och deras anvendning | |
| BR8306422A (pt) | Compostos,processo para sua preparacao,composicao,processos para sua preparacao e para o combate ou prevencao de uma infestacao por microorganismos,emprego e oxiranas | |
| ES8503355A1 (es) | Procedimiento de preparacion de nuevas sales de derivados organofosforados | |
| SE8302347L (sv) | Bensoazacykloalkyl-spiro-imidazolidiner, framstellning derav och farmaceutiska kompositioner innehallande dem | |
| ES8304536A1 (es) | "procedimiento para la preparacion de nuevas fenilalcohilaminas". | |
| SE7704240L (sv) | Bis-kvaternera pyridinium-2-aldowim-salter och forfarande for framstellning derav | |
| DK337883A (da) | Fremgangsmaade til fremstilling af muramylpeptider eller salte deraf | |
| YU196990A (sh) | Herbicidi derivati 2-azolil-nikotinata | |
| ATE19242T1 (de) | Substituierte pyrimidin-2-one und deren salze. | |
| GB1069797A (en) | ª-aminoketone derivatives | |
| GR74679B (es) | ||
| SE8302481D0 (sv) | Carbazic acid derivatives, process for their preparation and compositions containing the same | |
| AR240825A2 (es) | Procedimiento para obtener compuestos de 7-(2-aminotiazol-4-il-acetamido-3(((1-(2-dimetil aminoetil)-1h-tetrazol-5-il)tio)metil)-cef-3-em-4-carboxilato y sus sales | |
| ES535899A0 (es) | Un procedimiento para la preparacion de nuevos derivados de aminoalcoholes. | |
| ES2002392A6 (es) | Un procedimiento para la preparacion de esteres del acido 9,10- dihidrolisergico. | |
| ES8203370A1 (es) | Procedimiento de preparar 6-hidrazonopirido(2,1-b)quinazo- lin-11-onas y similares | |
| ES520269A0 (es) | Un procedimiento para la preparacion de una nueva piridazina sustituida. | |
| ES383390A1 (es) | Procedimiento para la preparacion de derivados de la dihi- dro - 10,11 dibenzo (b,f) azepina. | |
| PT100104A (pt) | Processo para a preparacao de aminoalcanos substituidos | |
| ES464480A1 (es) | Procedimiento para preparar esteres de acidos bencenosulfonicos sustituidos. | |
| MX3150E (es) | Procedimiento para preparar compuestos de 5 , 6 - di aril - 1 , 2 , 4 - tri azina | |
| ECSP972156A (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 233284 Country of ref document: ES |